Studies on the biochemical mechanism of the novel antitumor agent, CI-920.

Autor: Fry, David, Boritzki, Theodore, Jackson, Robert, Fry, D W, Boritzki, T J, Jackson, R C

Publikováno v: Cancer Chemotherapy & Pharmacology; Oct1984, Vol. 13 Issue 3, p171-175, 5p

Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity:  Design, Synthesis, and X-ray Cocrystal Structure

Autor: Koch, S. S. Canan, Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X.-H., Zook, S. E., Kumpf, R. A., Zhang, C., Boritzki, T. J., Mansour, R. N., Zhang, K. E., Ekker, A., Calabrese, C. R., Curtin, N. J., Kyle, S., Thomas, H. D., Wang, L.-Z., Calvert, A. H., Golding, B. T., Griffin, R. J., Newell, D. R., Webber, S. E., Hostomsky, Z.

Publikováno v: Journal of Medicinal Chemistry; November 2002, Vol. 45 Issue: 23 p4961-4974, 14p

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

Autor: Patick, A K, Boritzki, T J, Bloom, L A

Publikováno v: Antimicrobial Agents and Chemotherapy; October 1997, Vol. 41 Issue: 10 p2159-2164, 6p

Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.

Autor: Faessel HM; Grace Cancer Drug Center and Department of Biomathematics, Roswell Park Cancer Institute, New York State Department of Health, Buffalo 14263, USA., Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR

Publikováno v: Cancer research [Cancer Res] 1998 Jul 15; Vol. 58 (14), pp. 3036-50.

AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.

Autor: Boritzki TJ; Agouron Pharmaceuticals Inc., San Diego, CA 92121, USA., Barlett CA, Zhang C, Howland EF

Publikováno v: Investigational new drugs [Invest New Drugs] 1996; Vol. 14 (3), pp. 295-303.